Activities, Bill Numbers and Titles
|
|
Client: Novartis Services, Inc.
|
|
House Bill
|
1307
|
An Act establishing a study to examine the feasibility of state manufactured generic prescription drugs
|
Neutral
|
$179.00
|
N/A
|
Senate Bill
|
771
|
An Act relative to pharmaceutical access, costs and transparency
|
Neutral
|
$632.00
|
N/A
|
House Bill
|
1254
|
An Act relative to promoting comprehensive transparency in the pharmaceutical industry
|
Neutral
|
$632.00
|
N/A
|
Senate Bill
|
736
|
An Act relative to promoting comprehensive transparency in the pharmaceutical industry
|
Neutral
|
$632.00
|
N/A
|
Senate Bill
|
786
|
An Act to bring down the cost of prescription drugs
|
Neutral
|
$158.00
|
N/A
|
Executive
|
Department of Public Health (DPH)
|
Meeting with Department of Public Health on the newly established Rare Disease Advisory Council
|
Neutral
|
$375.00
|
N/A
|
House Bill
|
729
|
An Act to ensure prescription drug cost transparency and affordability
|
Neutral
|
$237.00
|
N/A
|
Senate Bill
|
790
|
An Act to define modest meals and refreshments in prescriber education settings
|
Neutral
|
$135.00
|
N/A
|
Senate Bill
|
804
|
An Act to promote transparency and prevent price gouging of pharmaceutical drug prices
|
Neutral
|
$135.00
|
N/A
|
House Bill
|
1278
|
An Act relative to prescription drug price transparency
|
Neutral
|
$158.00
|
N/A
|
House Bill
|
1272
|
An Act to promote transparency in prescription drug prices
|
Neutral
|
$158.00
|
N/A
|
| | |
Total amount
|
$3,431.00
| |
|
|
|
Meals, Travel, and Entertainment Expenses
|
No meals, travel, or entertainment expenses were filed for this disclosure reporting period. |
|
|
Additional Expenses
|
No additional expenses were filed for this disclosure reporting period. |
|
|
Campaign Contributions
|
11/04/2021 |
The Committee to Elect Thomas Golden
|
State Representative; 16th district
|
$200.00
|
12/14/2021 |
House Victory Fund
|
House Democrats
|
$100.00
|
| | Total contributions |
$300.00
|
|